Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer

NCT06599216 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HR+/HER2- Breast Cancer

Interventions

DRUG: Adebrelimab+Dalpciclib+Standard Endocrine Therapy

Sponsor

Harbin Medical University